Injectable Multiple Sclerosis Medications (original) (raw)
The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study
Pamela Foulds Foulds
BMC Neurology, 2011
View PDFchevron_right
Will New Injection Devices for Interferon Beta-1a s.c. Affect Treatment Adherence in Patients With Multiple Sclerosis? An Expert Opinion in the Middle East
Ahmad Khalifa, Jihad Inshasi
International Journal of Neuroscience, 2011
View PDFchevron_right
Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study
Virginia Devonshire
BMC Neurology, 2010
View PDFchevron_right
A network meta-analysis of efficacy and evaluation of safety of subcutaneous Pegylated Interferon Beta-1a and injectable therapies for the treatment of relapsing-remitting multiple sclerosis.
Michael Hutchinson
View PDFchevron_right
The STAR Study: A Real-World, International, Observational Study of the Safety and Tolerability of, and Adherence to, Serum-Free Subcutaneous Interferon β-1a in Patients With Relapsing Multiple Sclerosis
Hanna Kuusisto
Clinical Therapeutics, 2014
View PDFchevron_right
Treatment Discontinuation and Disease Progression with Injectable Disease-Modifying Therapies
Genevieve Laforet
International journal of MS care, 2013
View PDFchevron_right
Treatment discontinuation and disease progression with injectable disease-modifying therapies: findings from the north american research committee on multiple sclerosis database
Genevieve Laforet
International journal of MS care, 2013
View PDFchevron_right
Best practices in skin care for the multiple sclerosis patient receiving injectable therapies
Colleen Harris
International Journal of …, 2010
View PDFchevron_right
Glatiramer acetate versus interferon Beta-1a for subcutaneous administration: Comparison of outcomes among multiple sclerosis patients
Jane Castelli-Haley
Advances in Therapy, 2008
View PDFchevron_right
Injectable disease modifying agents in multiple sclerosis: pattern of medication use and clinical effectiveness
Marja-Liisa Sumelahti
Neurology International
View PDFchevron_right
Treatment of multiple sclerosis — success from bench to bedside
Mar Tintoré
Nature Reviews Neurology
View PDFchevron_right
Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practice
Anne Cross
Multiple sclerosis journal - experimental, translational and clinical
View PDFchevron_right
Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register
Damiano Paolicelli
Neurotherapeutics, 2021
View PDFchevron_right
Comparative tolerance of IFN beta-1a regimens in patients with relapsing multiple sclerosis
Yves Lapierre
Journal of Neurology, 2005
View PDFchevron_right
Patient satisfaction following transition from the original to the new formulation of subcutaneous interferon beta-1a in relapsing multiple sclerosis: a randomized, two-arm, open-label, Phase IIIb study
Dieter Poehlau
Patient Preference and Adherence, 2010
View PDFchevron_right
Persistence and adherence to interferon and glatiramer acetate in patients with multiple sclerosis
Patricia Sanmartin
European Journal of Hospital Pharmacy, 2017
View PDFchevron_right
Fostering adherence to injectable disease-modifying therapies in multiple sclerosis
Alessandra Lugaresi, Francesco Patti
Expert Review of Neurotherapeutics, 2014
View PDFchevron_right
Early predictors of injectable disease modifying drugs suboptimal response based on clinical and radiological data assessment in Polish Multiple Sclerosis patients
Dorota Koziarska
Neurologia i Neurochirurgia Polska
View PDFchevron_right
Adherence to self-administering interferon-β1a using RebiSmart® device in Mexican patients with relapsing multiple sclerosis
Erwin Chiquete
PLOS ONE
View PDFchevron_right
Best Practices in Multiple Sclerosis
June Halper CEO
Journal of Infusion Nursing, 2010
View PDFchevron_right
ExtaviJect® 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study
Ivan Milanov
Medical Devices: Evidence and Research, 2013
View PDFchevron_right
Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study
Jeptha Davenport
PloS one, 2015
View PDFchevron_right
Patient satisfaction with an injection device for multiple sclerosis treatment
Joyce Cramer
Acta Neurologica Scandinavica, 2006
View PDFchevron_right
Real-life outcomes for oral disease-modifying treatments of relapsing-remitting multiple sclerosis patients: Adherence and adverse event profiles from Marmara University
Dilek Gunal
Turkish Journal of Medical Sciences
View PDFchevron_right
Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study
Juhani Ruutiainen, G. Karas, Ronald A van Schijndel, F. Dahlke, Sten Fredrikson
Multiple Sclerosis, 2003
View PDFchevron_right
Bridging Therapies With Injectable Immunomodulatory Drugs in the Management of Multiple Sclerosis: A Delphi Survey of an Italian Expert Panel of Neurologists
valentina panetta
Frontiers in Neurology
View PDFchevron_right
Perspectives and experiences of Dutch multiple sclerosis patients and multiple sclerosis-specialized neurologists on injectable disease-modifying treatment
Karin Van Der Hiele
Patient Preference and Adherence, 2016
View PDFchevron_right